Table 3.
Influence of TCZ in comparison with other treatment groups.
| Anti-inflammatory treatment |
p-value | ||||
|---|---|---|---|---|---|
| TCZ | Anti-TNF | JAK-i | Other | ||
| Age (years), median (IQR) | 75.28 (65.3–85.24) | 45.79 (31.93–64.06) | 64.01 (51.66–81.16) | 62.1 (56.17–79.63) | <0.001 |
| Male | 35.7% | 49.0% | 22.7% | 28.9% | 0.006 |
| Diagnosis of infectious disease on admission | 50.0% | 22.4% | 38.1% | 26.7% | 0.040 |
| CRP (mg/dL), median (IQR) | 0.5 (0.05–21.21) | 24.09 (6.54–91.81) | 19.64 (6.65–76.71) | 93.32 (16.95–172.16) | <0.001 |
| WBC (K/μL), median (IQR), | 9.25 (6.4–11.53) | 8.6 (6.4–11.1) | 7.45 (5.08–9.88) | 7.8 (5.95–12.95) | 0.315 |
TCZ - Tocilizumab; TNF - Tumor necrosis factor; JAK - Janus kinase inhibitors; CRP - C-reactive protein; WBC - White blood cells.